Researchers at Sahlgrenska Academy, University of Gothenburg, in Sweden have found that antioxidants can double the rate of melanoma metastasis in mice. The results reinforce previous findings that antioxidants hasten the progression of lung cancer, researchers said.
According to professor Martin Bergo, people with cancer or an elevated risk of developing the disease should avoid nutritional supplements that contain antioxidants. Researchers demonstrated last year that antioxidants hastened and aggravated the progression of lung cancer.
Mice that were given antioxidants developed additional and more aggressive tumours. Experiments on human lung cancer cells confirmed the results.
Found in many nutritional supplements, antioxidants are widely marketed as a means of preventing cancer. The follow-up studies have now found that antioxidants double the rate of metastasis in malignant melanoma, the most perilous type of skin cancer. "As opposed to the lung cancer studies, the primary melanoma tumour was not affected," Bergo said.
"But the antioxidant boosted the ability of the tumour cells to metastasise, an even more serious problem because metastasis is the cause of death in the case of melanoma. The primary tumour is not dangerous per se and is usually removed," he said.
Experiments on cell cultures from patients with malignant melanoma confirmed the new results, researchers said.
"We have demonstrated that antioxidants promote the progression of cancer in at least two different ways," Bergo said.
The overall conclusion from the various studies is that antioxidants protect healthy cells from free radicals that can turn them into malignancies but may also protect a tumour once it has developed.
Taking nutritional supplements containing antioxidants may unintentionally hasten the progression of a small tumour or premalignant lesion, neither of which is possible to detect, researchers said.
"Our current research combined with information from large clinical trials with antioxidants suggests that people who have been recently diagnosed with cancer should avoid such supplements," Bergo added.
The study was published in the journal Science Translational Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)